Anti-Human FGF R4

Leinco Technologies
Product Code: LEI-F1080
Product Group: Primary Antibodies
CodeSizePrice
LEI-F1080-25ug25 ug£375.00
Quantity:
LEI-F1080-100ug100 ug£648.00
Quantity:
LEI-F1080-500ug500 ug£648.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG2a
Antibody Clonality: Monoclonal
Antibody Clone: 137114
Regulatory Status: RUO
Target Species: Human
Application: Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.

Further Information

Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Formulation:
This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Immunogen:
NS0-Derived Recombinant Human FGF R4 Extracellular Domain (Accession # P22455)
Long Description:
Fibroblast growth factor receptor 4 (FGFR4) is a member of a family of transmembrane receptors with ligand-induced tyrosine kinase activity1 that is expressed at significant levels in almost all human prostate cancers, and expression of its ligands is ubiquitous.2 FGFR4 plays essential roles in systemic lipid and glucose homeostasis.3 FGFR4 may be an important regulator of osteogenesis with involvement in preosteoblast proliferation and differentiation as well as osteoblast functioning during intramembranous ossification.4 FGFR-4 signaling and receptor turnover are important potential therapeutic targets in prostate cancer.2
NCBI Gene:
2264
Target:
FGF R4

References

1. Habuchi, T. et al. (2008) Int J Cancer 123: 2574 2. Ittmann, MM. et al. (2008) Neoplasia 10: 847 3. McKeehan, WL. et al. (2007) Diabetes 56: 2501 4. Nurcombe, V. et al. (2002) Int J Dev Biol. 46: 519